Shandong Province 'Outstanding Youth' (2024): Provincial Level
Pudong New Area 'Mingzhu Elite Talent' (2023): Other
Shandong Province Taishan Scholar Young Expert (2023): Provincial Level
Shanghai Outstanding Young Academic Leader (2022): Provincial Level
Shanghai Youth Science and Technology Star (2017): Provincial Level
National High-Level Talent Introduction Youth Talent (2017): National Level
Shanghai Pharmaceutical Science and Technology Award, Second Prize (2012): Provincial Level
Research
Epigenetic Innovative Drug Research Medicinal Chemistry C-H Activation Methodology
Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury, Bing Zhou, 2023
Discovery of Highly Potent and Selective Thyroid Hormone Receptor Agonists for the Treatment of Nonalcoholic Steatohepatitis, Bing Zhou, 2023
Discovery of a Potent and Selective Degrader for USP7, Bing Zhou, 2022
The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma, Bing Zhou, 2022
Rh(III)-catalyzed twofold unsymmetrical C-H alkenylation-annulation/amidation reaction enabled delivery of diverse furoquinazolinones, Bing Zhou, 2022
Discovery of novel Thieno2,3-dimidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration, Bing Zhou, 2022
Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors, Bing Zhou, 2022
Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1), Bing Zhou, 2022
Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis, Bing Zhou, 2022
A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1 and IL-6, Bing Zhou, 2022
Rhodium(III)-Catalyzed Asymmetric 1,2-Carboamidation of Alkenes Enables Access to Chiral 2,3-Dihydro-3-benzofuranmethanamides, Bing Zhou, 2022
The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma, Bing Zhou, 2022
Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer, Bing Zhou, 2021
Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3, Bing Zhou, 2021
Rh(III)-catalyzed selective C7-H functionalization of indolines with 1,3-enynes enables access to six-membered 1,7-fused indolines, Bing Zhou, 2021
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders, Bing Zhou, 2021
Inhibition of autophagy by a small molecule through covalent modification of LC3 Protein, Bing Zhou, 2021
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors, Bing Zhou, 2021
Rh(III)-catalyzed tandem annulative redox-neutral arylation/amidation of aromatic tethered alkenes, Bing Zhou, 2020
Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain, Bing Zhou, 2020
Ruthenium(II)-Catalyzed Regioselective C-H Hydroxymethylation of N-Aryl-azaindoles with Paraformaldehyde, Bing Zhou, 2020
Ruthenium(II)-Catalyzed Regioselective Ortho C-H Allenylation of Electron-Rich Aniline and Phenol Derivatives, Bing Zhou, 2020
Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion, Bing Zhou, 2020
Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors, Bing Zhou, 2020
BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma, Bing Zhou, 2020
Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors, Bing Zhou, 2020
Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-terminal (BET) Bromodomain Inhibitors, Bing Zhou, 2020
Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys, Bing Zhou, 2019
p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization, Bing Zhou, 2019
Ru(II)-catalyzed regioselective C-7 hydroxymethylation of indolines with formaldehyde, Bing Zhou, 2019
Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors, Bing Zhou, 2019
Rh(III)-catalyzed Redox-Neutral Unsymmetrical C-H Alkylation and Amidation Reactions of N-Phenoxyacetamides, Bing Zhou, 2018
Rh(III)-Catalyzed C-H Functionalization of Indoles with Diazo Compounds: Facile Synthesis of Structurally Diverse 2,3-Fused Indoles, Bing Zhou, 2018
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor, Bing Zhou, 2018
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression, Bing Zhou
Area of Focus
Liver Cancer | Dna | Methylation | Biomarkers | Cancer Research | Molecular Biology | Genetics | Oncology | Medical Research | Clinical Trials
